Data Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up To 95% And Halts Metastasis In A Model Of Hormone-Re

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, announced that preclinical data presented at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) shows that a mouse equivalent of Peregrine's anti-phosphatidylserine (anti-PS) vascular targeting antibody bavituximab administered in combination with the chemotherapeutic agent docetaxel demonstrated excellent signs of efficacy in a preclinical model of hormone-refractory prostate cancer. These new data confirm and extend the results of previous studies of Peregrine's anti-PS antibodies in models of prostate cancer. They were described...